Candel Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.90next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly194.8MTarget: Sufficient to fund operations into Q1 2028
Aglatimagene Besadenovec (CAN-2409) Phase 3 Prostate Cancer BLA Submission Progress QuarterlyTarget: BLA Submission in Q4 2026
Aglatimagene Besadenovec (CAN-2409) Pivotal Phase 3 NSCLC Trial Initiation QuarterlyTarget: Initiation in Q2 2026
Watch Items
- Process validation with Contract Development and Manufacturing Organization (CDMO) for CAN-2409Trigger: Completion of process validation batches in Q2 2026Action: Ensure CMC (Chemistry, Manufacturing, and Controls) data is ready to support the planned Q4 2026 BLA filing.
- Mature overall survival (OS) data and Phase 2 initiation for Linoserpaturev (CAN-3110) in recurrent high-grade gliomaTrigger: Publication of updated Phase 1b OS data and biomarker analysis in mid-2026Action: Evaluate clinical efficacy of repeat injections to support potential randomized controlled Phase 2 dose regimen finding study.
Research as of 20 Jun 2026